CA-AGENDIA-INC
11.12.2020 15:47:12 CET | Business Wire | Press release
Agendia, Inc. , a world leader in precision oncology for breast cancer, today announced that additional data from its groundbreaking MINDACT study will be highlighted in an oral presentation by Laura van ’t Veer, Ph.D., Co-founder and Chief Research Officer, at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020). These data highlight the ability of MammaPrint® , Agendia’s 70-gene breast cancer recurrence assay, to further stratify patients with clinically low risk breast cancer which could impact physician-patient discussions and treatment planning.
MINDACT (Microarray In Node-Negative and 1-3 node-positive Disease may Avoid ChemoTherapy), the Phase 3, prospective, randomized clinical trial supported by the European Organization for Research and Treatment of Cancer (EORTC), was designed to determine whether MammaPrint could be used to safely de-escalate patients with early stage breast cancer from chemotherapy without compromising their outcomes. Updated outcome and treatment data from the trial shared at SABCS 2020 build upon nearly 9-year follow-up results debuted at ASCO 2020 and confirm MINDACT as a positive de-escalation study.
Dr. van ’t Veer’s presentation showed that the combination of clinical low risk and MammaPrint Low Risk results indicate excellent 8-year prognosis – these patients showed a distant metastasis-free survival rate of 94.7% with no chemotherapy. Of note, amongst the clinically low risk study population, distant metastasis free survival at 8 years was 3.6% better in MammaPrint Low Risk patients as compared to those with a High Risk result.
“Collectively, these data produce a significant library of evidence that will allow for the precise treatment of breast cancer, including insights into a patient population considered low risk,” said Dr. van ’t Veer. “Within this population, further stratification by genomic signature into MammaPrint Low or High Risk should be weighed for further treatment planning.”
These data are part of a large suite of 13 posters, spotlight sessions and an oral presentation on MammaPrint and BluePrint that were accepted to SABCS 2020, and underscore Agendia’s mission to help guide the diagnosis and personalized treatment of breast cancer for all patients throughout their treatment journey.
About Agendia
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.
MammaPrint® , the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint® , the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.
Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.
Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201211005005/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Uniswap Labs and Securitize Collaborate to Unlock Liquidity Options for BlackRock’s BUIDL11.2.2026 15:00:00 CET | Press release
New integration pairs the efficiencies of Uniswap’s technology with the familiarity of traditional markets, enables near instant liquidity between BUIDL and USDC for investors Uniswap Labs, the leader in decentralized finance, and Securitize, the leader in tokenizing real-world assets (RWAs), today announced a strategic integration to make BlackRock USD Institutional Digital Liquidity Fund (BUIDL) shares available to trade via UniswapX technology. This integration will enable onchain trading of BUIDL, both unlocking new liquidity options for BUIDL holders, and marking a significant step in bridging the gap between traditional finance and DeFi. “Our mission at Labs is simple: make exchanging value cheaper, faster and more accessible,” said Hayden Adams, Uniswap Labs Founder and CEO. “Enabling BUIDL on UniswapX with BlackRock and Securitize supercharges our mission by creating efficient markets, better liquidity, and faster settlement. I’m excited to see what we build together.” Securiti
Calvin McDonald Joins The Wella Company as CEO11.2.2026 14:30:00 CET | Press release
--Industry Veteran with Track Record of Scaling Global Brands----Proven Leadership Driving Market Share and Profitable Growth-- The Wella Company, an innovative global beauty leader, today announced that Calvin McDonald has been chosen as the company’s next Chief Executive Officer, effective April 2, 2026. Calvin will also be appointed to the company’s Board of Directors and will be based in New York. Glenn Murphy will remain as Executive Chair to provide continuity as well as strategic advice to the new CEO and the leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210093439/en/ Calvin McDonald “We are delighted to welcome Calvin to The Wella Company,” said Glenn Murphy, Executive Chair. “As a three-time CEO, he brings decades of experience at industry-leading global consumer brands and retail businesses. Calvin’s proven ability to drive results through product differentiation, category expansion, and smart
Corpay Cross-Border Extends Exclusive Partnership with LIV Golf11.2.2026 14:30:00 CET | Press release
Corpay will continue to provide LIV Golf access to innovative global payments and comprehensive currency risk management solutions Corpay, Inc.* (NYSE: CPAY), a global leader in corporate payments, today announced that its Cross-Border business has entered into a multi-year agreement to extend its successful and exclusive collaboration with LIV Golf, as its Official Corporate Foreign Exchange (FX) Provider. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211636852/en/ Since 2024, Corpay Cross-Border has delivered a range of corporate foreign exchange payment solutions to LIV Golf. With this multi-year extension, the League will continue to benefit from Corpay’s comprehensive currency risk management solutions and award-winning global payments platform. “Over the past two seasons, we’ve had the privilege of being the Official Corporate FX Provider for LIV Golf,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border
Energy Vault and Crusoe Announce Strategic Framework Agreement for Deployment of Crusoe Spark Modular AI Factory Units to DeliverCrusoe Cloud11.2.2026 14:30:00 CET | Press release
Multi-year framework enables rapid, phased deployments up to 25 MWbeginning in 2026, leveraging Energy Vault’s critical energy infrastructure capabilities and digital operating platform to deliver “powered shell” modular data center capacityFirst deployment planned at Energy Vault’s Snyder, Texas solar generation and energy storage technology centerto accelerate time-to-capacity for Crusoe CloudcustomersAgreement marks Energy Vault’s entry into the AI Infrastructure market, unlocking access to revenue-per-MW up to 20× higher than traditional BESS deployments, significantly accelerating Energy Vault’s EBITDA generation and scaling the Asset Vault platform Energy Vault Holdings, Inc. (NYSE: NRGV) (“Energy Vault”), a global leader in grid-scale energy storage solution infrastructure, and Crusoe, the industry’s first vertically-integrated AI infrastructure provider, today announced a strategic framework agreement for the phased deployment of Crusoe Spark modular data centers at Energy Vaul
INNIO Secures Additional Major Order from VoltaGrid: 1.5 GW for Behind-the-Meter Power Generation11.2.2026 14:00:00 CET | Press release
INNIO and VoltaGrid have signed an agreement to supply 1.5 gigawatts (GW) of behind-the-meter power generation infrastructure, including 300 Jenbacher gas engines The order comprises Jenbacher gas engines to support AI and high‑performance computing data centers INNIO Group today announced a major order from VoltaGrid for 1.5 gigawatts (GW), reinforcing the companies’ collaboration in behind‑the‑meter (on-site) power generation for AI and high‑performance computing infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211822384/en/ INNIO's Jenbacher J624 gas engine Under the agreement, INNIO expects to supply a total of 300 Jenbacher gas engines from its Type J624 and Type J620 series. The J624 series is integrated into VoltaGrid’s proprietary QPac™ platform. The engines are packaged into 25 MW units, enabling rapid, scalable deployment for data center customers across the United States. Delivery is scheduled by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom